Trial Profile
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa) (Primary)
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Oct 2012 Planned end date changed from 1 Jan 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 12 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.